KRAS and lung cancer: For our work, we used a panel of nine human and mouse lung cancer cell lines (sensitive or CTD-resistant) with diverse mutational/oncogenic driver profiles (i.e., KRAS G12 mutants, MET amplification, EGFR exon 19 deletion, among others) (Fig. 3b).